Cite

HARVARD Citation

    Nakhaipour, H. et al. (2021). Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada. Journal of medical economics. pp. 1525-1533. [Online]. 
  
Back to record